For Sale – Popular K-Pop Online & Offline Retail Store in Buena Park Shopping Center Exciting opportunity to own a thriving K-Pop specialty store located in a busy Buena Park shopping mall! This well-established store offers a wide selection of today’s hottest K-Pop albums, accessories, gifts, and merchandise — appealing to dedicated fans and casual shoppers alike. Key Features: Prime location in a high-traffic retail center Sells trending K-Pop albums, official merchandise, accessories, and more Additional income streams from an in-store photo booth and claw machine Strong social media presence and loyal customer base Ideal for anyone passionate about K-Pop or looking to enter a high-demand niche market. Serious inquiries only, please. Don’t miss out on this exciting opportunity to own a unique and growing retail business!

This painting company has been stable, but they have seen sustained growth and have been one of the fastest growing small business painting companies in the Vancouver/Portland area. Starting in 2013, annual had already eclipsed half a million by 2019. With a work-from-home office, this business provides the ability to manage safely out of your own home or to be able to choose your ideal location to rent. Strong customer ratings and consistently high levels of service have made this an ideal business for anyone looking to establish a presence in the painting industry or to expand your current painting business territory and customer base. Detailed Information Employees:2 FTE Support & Training: Seller will negotiate a transition period Reason for Selling: Relocation

Asset Sale – Fully Equipped Wellness & Fitness Studio An outstanding opportunity to acquire a turnkey wellness business! This asset sale includes all fitness and Pilates equipment, making it ideal for a fitness studio, personal training, or group classes. The space also features three private treatment rooms — perfect for physical therapy, acupuncture, beauty care, or other wellness services. Highlights: Complete set of fitness & Pilates equipment included 3 fully equipped private rooms for therapy or treatment services Ideal setup for a multi-service wellness center Clean, modern, and move-in ready Whether you're expanding your current business or launching a new venture, this is a rare opportunity to step into a fully operational space with minimal setup required.

Our client sources an excellent quality bourbon that has a higher yield than a traditional 6-8-year aged bourbon. Due to the higher yield because of less evaporation, they are able to keep the MSRP very competitive and are growing rapidly. They partner with a smaller craft distillery as their co-packer in order to keep production costs down. The founder is a rising, Tennessee-based singer/songwriter with thousands of followers. He uses, and will continue to use, his social media and concerts to publicize the bourbon and allows fans to become partial minority owners of the brand, thus far garnering approximately $200,000 as of the beginning of December 2022. Since the launch of the bourbon brand in 2018 it has earned some of the largest and most prestigious awards which can be awarded in the spirit industry. 1) Named Top 6 in the World in Forbes 2) Featured in Billboard, Rolling Stone, Uproxx, American Songwriter 3) Platinum Los Angeles 4) Double Gold San Francisco (largest award in the world for whiskey to earn) 5) Double Gold New York International 6) Double Gold New York Best Fifty 7) Gold Las Vegas 8) Silver Denver Our client has created a supportive community of real fans who love both the founder's music and the bourbon. Our client has taken the brand as far as 26 states. They will soon expand into Canada and exporting to South Africa & Vietnam is on the horizon. The founder and his partner are willing to stay on the team to bring the Bourbon brand to a much higher national level with a well-capitalized strategic buyer or owner-operator who is passionate about the bourbon industry. An NDA is required to secure a comprehensive Confidential Information Memorandum (CIM). Growth & Expansion: In CIM - NDA Required. Financing: If the price and deal structure is right Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: Other Projects

Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

Our client operates a lean, high-margin B2B lead-generation platform dedicated to the Internet of Things sector. By leveraging a permission-based community of over 60,000 vetted IoT decision-makers and a LinkedIn Group of 20,000+ approved professionals, they deliver turnkey sponsored webinars, white-paper campaigns, and targeted email blasts—providing technology vendors with consistently qualified leads while maintaining minimal overhead through a fully remote, contractor-driven model. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Confidential Information Memorandum (CIM) available upon receipt of our short online NDA. * It is estimated that the marketplace for connected cars and automobile data is will reach $400BN by 2030. * There are currently ~280MM registered automobiles in the US today with ~65MM of them being connected cars * The Company has created a process that while working with 3rd party Companies in the space and simultaneously creating a near proprietary technology is able to harness processes related to car data, thereby creating an opportunity for Companies looking to enter the aftermarket space for consumers and/or enterprises already in the automobile space, * Ideally this would be an add-on solution for any Company that is in the fleet-auto space, or looking to create an expansive and/or sweeping platform for the Consumer space NDA is required to secure comprehensive Confidential Information Memorandum (CIM). Detailed Information: Facilities: Home Based Competition: Few if any Growth & Expansion: Ample Financing: Depending on offer and structure may be acceptable minimal if any Support & Training: As needed. Reason for Selling: Existing opportunities

Our client is offering a next generation, patented medical device for the treatment of internal hemorrhoids. The procedure is painless, non-invasive, requires no anesthesia, is conducted in under 2 minutes, and can be performed in any medical setting: a doctor's office, a surgery center, an endo suite, or a hospital. Our client's product is a small, disposable, medical device that eliminates hemorrhoids. A physician uses this device by deploying a tiny rubber band on the base of the hemorrhoid. This procedure is known as rubber band ligation, and it is the #1 recommended treatment for internal hemorrhoids by the American College of Gastroenterology. Patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. The device is currently manufactured in the USA through an FDA approved, ISO 13485 contract manufacturer, who specializes in medical devices. The device is sold directly to physicians of different specialties, including gastroenterologists, colorectal surgeons, GYNs, urologists and primary care physicians. The biggest targeted audience are gastroenterologists. NDA is required to secure comprehensive Confidential Information Memorandum. Growth and epansion: Nearly half of adults over the age of 50 will develop symptomatic hemorrhoids. In the U.S. alone, an estimated 60,000,000 people have experienced hemorrhoid symptom(s) at some point in their lives. Annually, over 20,000,000 people in the U.S. use an over-the-counter hemorrhoid treatment and 75% report a reoccurrence. These patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. Financing is if the price and deal structure is right, and support and training is provided as required. Facilities are Outlined in CIM. Reason for selling is that the owners wish to move on to other projects.